A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
复制标题

活体衰减的HSV-2 ICP0病毒比糖蛋白D亚基疫苗更大的保护剂对生殖器疱疹的保护大10到100倍。

DOI:
10.1371/journal.pone.0017748
复制
发表时间:
2011-03-11
期刊:
影响因子:
3.7
通讯作者:
Rakowski B
Rakowski B
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Halford WP;Püschel R;Gershburg E;Wilber A;Gershburg S;Rakowski B

文献摘要

参考文献

被引文献

相似文献

糖蛋白D(gD-2)是单纯疱疹病毒2型(HSV-2)的进入受体,并且是制药工业的主要HSV-2候选疫苗中的免疫原。使用gD-2亚单位疫苗预防生殖器疱疹的努力已经持续了20年,成本超过1亿美元。迄今为止,gD-2疫苗在临床试验中产生了不确定的保护作用。因此,使用小动物模型,我们试图确定减毒HSV-2 ICP 0 −活病毒是否比gD-2亚单位疫苗更能预防生殖器疱疹。用gD-2和有效佐剂(明矾+单磷酰脂质A)免疫的小鼠产生高滴度的gD-2抗体。虽然gD-2免疫的小鼠对HSV-2具有显著的抗性,但45只gD-2免疫的小鼠中只有3只在用野生型HSV-2(MS株)对阴道或眼睛的压倒性攻击中存活。相比之下,用HSV-2 ICP 0 −活病毒0ΔNLS免疫的115只小鼠中有114只在相同的HSV-2 MS挑战中存活。同样,0Δ NLS免疫小鼠每个阴道排出的HSV-2 MS攻击病毒平均比gD-2免疫小鼠少125倍。体内成像表明,表达HSV 2攻击病毒的HSV 2在0Δ NLS免疫的小鼠中未能建立可检测的感染,而相同的病毒容易感染未感染和gD-2免疫的小鼠。总的来说,这些结果表明,HSV-2疫苗可能更有可能预防生殖器疱疹,如果它包含一个活的减毒HSV-2病毒,而不是一个单一的HSV-2蛋白。
Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To date, gD-2 vaccines have yielded equivocal protection in clinical trials. Therefore, using a small animal model, we sought to determine if a live-attenuated HSV-2 ICP0 − virus would elicit better protection against genital herpes than a gD-2 subunit vaccine. Mice immunized with gD-2 and a potent adjuvant (alum+monophosphoryl lipid A) produced high titers of gD-2 antibody. While gD-2-immunized mice possessed significant resistance to HSV-2, only 3 of 45 gD-2-immunized mice survived an overwhelming challenge of the vagina or eyes with wild-type HSV-2 (MS strain). In contrast, 114 of 115 mice immunized with a live HSV-2 ICP0 − virus, 0ΔNLS, survived the same HSV-2 MS challenges. Likewise, 0ΔNLS-immunized mice shed an average 125-fold less HSV-2 MS challenge virus per vagina relative to gD-2-immunized mice. In vivo imaging demonstrated that a luciferase-expressing HSV-2 challenge virus failed to establish a detectable infection in 0ΔNLS-immunized mice, whereas the same virus readily infected naïve and gD-2-immunized mice. Collectively, these results suggest that a HSV-2 vaccine might be more likely to prevent genital herpes if it contained a live-attenuated HSV-2 virus rather than a single HSV-2 protein.
DOI: 10.1002/j.1460-2075.1984.tb02270.x
发表时间: 1984-01-01
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
EVERETT, RD
通讯作者: EVERETT, RD
DOI: 10.1128/iai.35.3.1125-1132.1982
发表时间: 1982-01-01
影响因子: 3.1
作者:
CENTIFANTOFITZGERALD, YM;VARNELL, ED;KAUFMAN, HE
通讯作者: KAUFMAN, HE
DOI: 10.1016/s0264-410x(98)00470-8
发表时间: 1999-04-09
期刊: VACCINE
影响因子: 5.5
作者:
Aurelian, L;Kokuba, H;Smith, CC
通讯作者: Smith, CC
DOI: 10.1016/0035-9203(52)90062-x
发表时间: 1952-01-01
影响因子: 2.2
作者:
DICK, GWA;GEE, FL
通讯作者: GEE, FL
DOI: 10.1001/archpedi.1968.02100010660004
发表时间: 1968-01-01
影响因子: --
作者:
DUPAN, RM;HUYGELEN, C;PRINZIE, A
通讯作者: PRINZIE, A